Saccharomyces boulardii

Saccharomyces boulardii
  • Gluten Free
  • Non-GMO
  • Vegetarian
  • Vegetable Caps

Naturally supports balanced intestinal flora and protects against some infectious diarrhea

  • Non-pathogenic probiotic yeast
  • Protects against imbalance in healthy gut flora
  • Support for antibiotic-associated and traveler's diarrhea
  • Promotes immune health
  • Provides 5+ billion organisms per capsule
  • Hypoallergenic and shelf stable at room temperature
  • Delayed release capsule to support viability through the intestinal tract

Login to Order

Product Information Sheet (PDF)

Saccharomyces boulardii is a non-pathogenic probiotic yeast that survives stomach acid to nourish the intestines, support the immune system and provide a favorable growth environment for the beneficial bacteria that support health and digestive comfort. Medical studies have shown the efficacy and safety of S. boulardii for a number of health challenges in both adults and children. These applications include protection against antibiotic-related diarrhea, recurrent C. difficile-related diarrhea and colitis, traveler's diarrhea, acute bacterial and viral diarrhea, inflammatory bowels and irritable bowels.

S. boulardii acts as a temporary flora that quickly achieves high concentrations in the GI tract. It is one of the few yeasts that survives best at human body temperatures and is able to colonize and persist in the gut.

Healthy gut flora protects against some occassional diarrheas. Antibiotic-associated diarrhea (AAD) is an example, as antibiotics deplete and disrupt the normal flora, and the resulting diarrhea may be due to changes in short chain fatty acid metabolism. A severe form of AAD is due to the pathogen Clostridium difficule. Recurrent C. difficile diarrhea is difficult to manage successfully as one recurrence makes further recurrences more probable, likely because antibiotics are needed to treat and thus the fecal flora remains imbalanced. Saccharomyces boulardii may be beneficial as an adjunct to antibiotics. Due to their fungal nature, the yeast cells of S. boulardii are antibiotic resistant.

Probiotic actions are strain specific and effectiveness of strains from the same species may be very different. S. boulardii is genetically and functionally distinct from brewer's yeast (S. cerevisiae) and different from pathogenic Candida species. Even though taxonomically assigned to the S. cerevisiae species, S. boulardii  is characterized by a number of genetic features providing them to be more suitable to the intestinal environment. Patient One's S. boulardii strain is identified and verified through a combination of the most advanced genetic techniques. 

Equally important to selecting an effective strain is selecting an effective preparation. Patient One's S. boulardii  is obtained through a patented controlled-temperature, low-vacuum drying process. This technique preserves whole yeast cells and provides greater stability over time. Our product is encapsulated in a delayed release, acid-resistant vegetable capsule for effective delivery into the intestinal tract.

Patient One Saccharomyces boulardii provides a minimum of 5 Billion viable organisms per capsule at encasulation and is stable at room temperature, making it convenient for travel.


  • Research has shown S. Boulardii helps neutralize toxins. Pathogens such as E. coli and Salmonella irreversibly bind to the cell wall of S. boulardii, causing reduced binding to intestinal cells. S. boulardii effectively competes against the bacterium C. difficile which is known to flourish during antibiotic use and is often the cause of GI disturbances following antibiotic use. S. boulardii has also been shown to compete against Candida colonization.
  • Researchers found that S. boulardii supports a healthy immune response and supports GI barrier function by maintaining a healthy inflammatory cycle in the GI tract. The double blind, placebo-controlled trial demonstrated that patients who took S. boulardii showed an increase in slgA levels and a subsequent reduction in CRP, an indicator of a balanced inflammatory response.


  1. L. Edwards-Ingram, P. Gitsham, N. Burton, G. Warhurst, I. Clarke, D. Hoyle, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.Applied and Environmental Microbiology. 2007738245867
  2. McFarland LV. Systematic review and meta-analysis of saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16(18): 2202-2222.
  3. McCullough MJ, Clemons KV, Mccosker JH, Stevens DA.Species identification and virulence attributes of Saccharomyces boulardii (nom. invade.) Journal of Clinical Microbiology. 199836926137
  4. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.
  5. Dig Dis Sci 2009; 54(1):15-8.
  6. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996;22(1): 200-1.
  7. Surawicz CM.The microbiota and infectious diarrhea]Gastroenterologie clinique et biologique. 2010Suppl 1:S2936Epub 2010/10/05. Le microbiote dans les diarrhees infectieuses.
  8. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics-- Saccharomyces boulardii. Alimentary pharmacology & therapeutics. 2007;26(6):767-78. Epub 2007/09/05.
  9. E. Im, C. Pothoulakis, Recent advances in Saccharomyces boulardii research] Gastroenterologie clinique et biologique. 2010Suppl 1:S6270Epub 2010/10/05. Progress recents dans la recherche sur Saccharomyces boulardii.
  10. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary pharmacology & therapeutics. 2010;32(9):1069-79.
  11. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile- Associated Enteropathies in Infants. J Ped Gastroenterol Nutr 1993; 16:419-425.
  12. Ozkan TB, Sahin E, Erdemir G, Budak F. Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response. J Int Med Res 2007; 35(2): 201-12.
  13. Kelesidis T., Pothoulakis C. Efficacy and safety of the probiotic S. boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol. 2012;5(2): 111-125.

Supplement Facts

Serving Size: 1 Capsule
Servings Per Container: 60
Amount Per Serving % Daily Value**
Saccharomyces boulardii

[contains min. 5 Billion Colony Forming Units (CFUs) per capsule at encapsulation]

250 mg
† Daily Value not established.

Suggested Use

Take 2 capsules daily as a dietary supplement, in divided doses between meals, or as directed by your health practitioner. Store in a cool, dry place.


If you are pregnant, nursing, or taking any medications, consult your health practitioner before use. Discontinue use and consult your health practitioner if any adverse reactions occur. Keep out of reach of children. Use only if safety seal is intact.

Saccharomyces boulardii Label